Mani Foroohar

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know

Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine

Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine

Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

What Pfizer's Coronavirus Vaccine Data Means For Moderna

Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline

Mani Foroohar Recent News

Moderna Analyst On 4 Coronavirus Vaccine Program Risks

Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus.

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutics areas.

AstraZeneca's Coronavirus Vaccine Setback 'Mixed Blessing' For Moderna: Analyst

Moderna Inc (NASDAQ: MRNA) shares, which shed over 13% Tuesday on an analyst downgrade, are reversing course — with a competitor'

Moderna Analyst Downgrades COVID-19 Vaccine Developer, Sees 'Changing Competitive Environment'

Competitive pressure could impair Moderna Inc's (NASDAQ: MRNA) ability to take advantage of its strong position in the coronavirus vaccine race, according to an analyst at SVB Leerink.

2 Moderna Analysts On Chances Of COVID-19 Vaccine Approval, Upcoming Catalysts

Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program.

Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale

After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreemen

Moderna Posts Q2 Beat, Reportedly Closes In On Coronavirus Vaccine Deal With Swiss Government

Moderna Inc (NASDAQ: MRNA) shares were moving to the downside Wednesday despite the coronavirus vaccine developer reporting forecast-beating second-quarter results and reports of a potential deal with the Sw

Moderna Shares Rebound As Biopharma Starts Late-Stage Coronavirus Vaccine Trial, Snags More Funding

Close on the heels of announcing additional BARDA funding for its coronavirus vaccine candidate mRNA-1273, Moderna Inc (NASDAQ: MRNA) said Monday tha

Moderna Analyst Says Odds Are Good For COVID-19 Vaccine Approval, But Valuation Overcooked

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine in development — mRNA-1273 — continues to inspire confidence among sell-side anal

Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'